ArticleCurrent pharmacology reports2015
Extracting the Benefit of Nexrutine
Article in Current pharmacology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.Nutrients · 2022Pooled it
- Exercise and Phellodendron amurense extract differentially impinge on oxidative stress response pathways in a mouse model of prostate cancer.Scientific reports · 2026Article
- Evaluating the effects of exercise and phellodendron amurense on cardiac function in a prostate cancer mouse model.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Article
- Antiproliferative Effect ofLife (Basel, Switzerland) · 2022Article
- Mitochondrial Metabolism in Melanoma.Cells · 2021Review
- NexrutinePhysiological reports · 2019Article
- Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.PloS one · 2019Article
- Screening the active compounds of Phellodendri Amurensis cortex for treating prostate cancer by high-throughput chinmedomics.Scientific reports · 2017Article
- Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.Molecular carcinogenesis · 2017Article
- Food-based natural products for cancer management: Is the whole greater than the sum of the parts?Seminars in cancer biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The current standard of care for prostate cancer includes hormone therapy, radiation therapy and radical prostatectomy, each with its own set of undesirable side effects. In this regard there is an unmet need to develop strategies that can prevent or delay the development of clinical prostate cancer. One potential area involves the use of natural compounds involving botanicals. Along these lines we have found that Nexrutine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.